Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics is attractive because its EP300 program has shown encouraging preclinical efficacy and tolerability in myeloma and DLBCL while avoiding the platelet toxicity that has constrained dual CBP/EP300 inhibitors. The company’s selectivity-focused approach, supported by data suggesting efficacy equivalent or superior to inobrodib with minimal platelet impact, strengthens the case that EP300 could become a cornerstone oncology asset with an IND expected in late 2027 and initial data potentially in 1H29. Fundamentally, the balance sheet also looks supportive, with approximately $168M of cash at Q2:26 and a restructuring expected to extend runway into H2:29, giving ample time to advance multiple preclinical programs toward the clinic.

Foghorn Therapeutics is facing a materially weaker fundamental profile after FHD-909 was discontinued for lack of efficacy, undermining the company’s only clinical-stage asset and the clearest proof point for its SMARCA2/4 synthetic-lethality platform. The decision also winds down the Lilly collaboration, removes partnered pipeline value, and leaves the company dependent on early preclinical programs such as oral I&I, EP300, and CBP degraders that still require substantial validation before IND filings in late ’27. Although the ~40% workforce reduction extends runway into H2:29 and cuts some costs, the investment case now rests on higher-risk, capital-dependent assets with limited visibility and meaningful clinical, regulatory, and commercial uncertainty.